Studies on tanapox virus

Knight, Janice C.; Novembre, FrancisJ.; Brown, Denise R.; Goldsmith, Cynthia S.; Esposito, Joseph J.

doi:10.1016/0042-6822(89)90113-x

Cited by 53 publications

(33 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…YLD was almost identical to Tanapox disease, and the viruses were originally felt to be the same. Knight et al differentiated Tanapox virus and YLD virus by restrictive mapping (19). All three viruses were cultivated by serial passage at the Center for Disease Control.…”

Section: In Vitro Comparison Of Yld Virus and Vv In Tumor Cellsmentioning

confidence: 99%

Yaba-Like Disease Virus: an Alternative Replicating Poxvirus Vector for Cancer Gene Therapy

Lee

McCart

et al. 2001

J Virol

View full text Add to dashboard Cite

Vaccinia virus is being investigated as a replicating vector for tumor-directed gene therapy. However, the majority of cancer patients have preformed immunologic reactivity against vaccinia virus, as a result of smallpox vaccination, which may limit its use as a vector. The Yaba-like disease (YLD) virus was investigated here as an alternative, replicating poxvirus for cancer gene therapy. We have demonstrated that the YLD virus does not cross-react with vaccinia virus antibodies, and it replicates efficiently in human tumor cells. YLD virus can be expanded and purified to high titer in CV-1 cells under conditions utilized for vaccinia virus. The YLD virus RNA polymerase was able to express genes regulated by a synthetic promoter designed for use in orthopoxviruses. We sequenced the YLD virus TK gene and created a shuttle plasmid, which allowed the recombination of the green fluorescent protein (GFP) gene into the YLD virus. In a murine model of ovarian cancer, up to 38% of cells in the tumor expressed the GFP transgene 12 days after intraperitoneal virus delivery. YLD virus has favorable characteristics as a vector for cancer gene therapy, and this potential should be explored further.Poxviruses have unique characteristics which make them appealing as vectors for cancer gene therapy (4, 25). They have been investigated as vectors for delivery of tumor-associated antigens, cytokines, and costimulatory molecules in cancer patients, for the development of an antitumor immune response (5,17,22,32). Recently, laboratory experiments have supported the utility of vaccinia virus (VV) as a vector for tumordirected delivery of genes for enzyme-prodrug therapy and sensitization to systemic treatment with tumor necrosis factor (13,15,30). A replicating virus has distinct advantages over nonreplicating vectors for these tumor-directed applications, as it leads to an increase in the percentage of cells within a tumor that express the therapeutic gene over time (23,35). VV is an efficient, replicating virus that leads to high levels of transgene expression, selectively in tumor tissue when delivered systemically, and this can lead to a significant antitumor response. Selective mutations of the virus may enhance tumor specificity (29) Clinical trials with intravascular delivery of mutant VV will likely be hampered by the high percentage of cancer patients with preformed immunity against the virus as a result of vaccination against smallpox. High levels of circulating antibody titers and cytotoxic T cells recognizing VV can be detected many years after vaccination, and it is likely that this preformed immune reactivity will prevent adequate infection and spread of VV throughout a tumor when used as a vector for tumor-directed gene therapy. An alternative replicating poxvirus vector may mediate the selective, high transgene expression within tumors, without immune cross-reactivity. In general, the host range for poxviruses that do not cross-react with orthopoxviruses is quite limited, and although members of the avipoxvirus genu...

show abstract

Section: In Vitro Comparison Of Yld Virus and Vv In Tumor Cellsmentioning

confidence: 99%

Yaba-Like Disease Virus: an Alternative Replicating Poxvirus Vector for Cancer Gene Therapy

Lee

McCart

et al. 2001

J Virol

View full text Add to dashboard Cite

show abstract

“…This virus produces a very distinct disease in primates that is characterized by epidermal histiocytomas of the head and limbs (7,12). Although the exact host reservoir of YMTV is not established, it is presumed that the immunomodulatory proteins expressed by this virus can at least partially cope with the primate/human immune system.…”

mentioning

confidence: 99%

Yaba Monkey Tumor Virus Encodes a Functional Inhibitor of Interleukin-18

Nazarian

Rahman

Werden

et al. 2008

J Virol

View full text Add to dashboard Cite

Interleukin-18 (IL-18) is a critical proinflammatory cytokine whose extracellular bioactivity is regulated by a cellular IL-18 binding protein (IL-18BP). Many poxviruses have acquired variants of this IL-18BP gene, some of which have been shown to act as viral virulence factors. Yaba monkey tumor virus (YMTV) encodes a related family member, 14L, which is similar to the orthopoxvirus IL-18BPs. YMTV 14L was expressed from a baculovirus system and tested for its ability to bind and inhibit IL-18. We found that YMTV 14L bound both human IL-18 (hIL-18) and murine IL-18 with high affinity, at 4.1 nM and 6.5 nM, respectively. YMTV 14L was able to fully sequester hIL-18 but could only partially inhibit the biological activity of hIL-18 as measured by gamma interferon secretion from KG-1 cells. Additionally, 17 hIL-18 point mutants were tested by surface plasmon resonance for their ability to bind to YMTV 14L. Two clusters of hIL-18 surface residues were found to be important for the hIL-18-YMTV 14L interaction, in contrast to results for the Variola virus IL-18BP, which has been shown to primarily interact with a single cluster of three amino acids. The altered binding specificity of YMTV 14L most likely represents an adaptation resulting in increased fitness of the virus and affirms the plasticity of poxviral inhibitor domains that target cytokines like IL-18.

show abstract

“…YMTV induces histiocytomas with characteristic microscopic morphology in soft tissue of monkeys and baboons (2,3) and humans (4). YLDV, as well as a third Yatapoxvirus, Tanapox, causes vesicular skin lesions in monkeys and humans (5,6). Furthermore, YMTV DNA has transforming activity in monkey cell lines (7).…”

mentioning

confidence: 99%

A poxvirus protein forms a complex with left-handed Z-DNA: Crystal structure of a Yatapoxvirus Zα bound to DNA

Lokanath²,

Quyền³

et al. 2004

Proc. Natl. Acad. Sci. U.S.A.

108

120

View full text Add to dashboard Cite

A conserved feature of poxviruses is a protein, well characterized as E3L in vaccinia virus, that confers IFN resistance on the virus. This protein comprises two domains, an N-terminal Z-DNA-binding protein domain (Z␣) and a C-terminal double-stranded RNA-binding domain. Both are required for pathogenicity of vaccinia virus in mice infected by intracranial injection. Here, we describe the crystal structure of the Z␣ domain from the E3L-like protein of Yaba-like disease virus, a Yatapoxvirus, in a complex with Z-DNA, solved at a 2.0-Å resolution. The DNA contacting surface of Yaba-like disease virus Z␣ E3L closely resembles that of other structurally defined members of the Z␣ family, although some variability exists in the ␤-hairpin region. In contrast to the Z-DNA-contacting surface, the nonbinding surface of members of the Z␣ family are unrelated; this surface may effect protein-specific interactions. The presence of the conserved and tailored Z-DNA-binding surface, which interacts specifically with the zigzag backbone and syn base diagnostic of the Z-form, reinforces the importance to poxvirus infection of the ability of this protein to recognize the Z-conformation. The Yaba monkey tumor virus (YMTV) and the closely related Yaba-like disease virus (YLDV) are members of the Yatapoxvirus family. Both viruses have double-stranded DNA genomes of Ϸ150 kilobase pairs and code for Ͼ150 proteins (1). YMTV induces histiocytomas with characteristic microscopic morphology in soft tissue of monkeys and baboons (2, 3) and humans (4). YLDV, as well as a third Yatapoxvirus, Tanapox, causes vesicular skin lesions in monkeys and humans (5, 6). Furthermore, YMTV DNA has transforming activity in monkey cell lines (7). The high similarity between the YLDV and YMTV was revealed with the recent sequencing of the Yaba monkey tumor virus (8).All sequenced poxviruses have a gene, called E3L in vaccinia, that is required for IFN resistance. E3L has been shown to be oncogenic and antiapoptotic; NIH 3T3 cells expressing vaccinia E3L were found to grow faster than control cells, with increased expression of cyclin A and decreased levels of the suppressor molecule p26 (9). When the NIH 3T3 E3L-expressing cells were injected into nude mice, solid tumors were formed. The expression of E3L has been shown to be essential for these oncogenic and antiapoptotic activities.The E3L protein and its orthologues comprise two domains, an N-terminal Z-DNA-binding protein domain (Z␣) and a C-terminal double-stranded RNA-binding domain. A similar Z␣ motif is found in vertebrate ADAR1 (double-stranded RNA adenosine deaminase) and in the IFN-inducible DLM-1 (also known as ZBP-1) of mammals (10, 11). Extensive biochemical and biophysical studies of human Z␣ ADAR1 show that it binds tightly and specifically to Z-DNA (10,(12)(13)(14). Both domains of the mouse-adapted vaccinia virus E3L are essential for pathogenicity in mice (15, 16). The C-terminal domain is sufficient for viral replication in cultured cells in vitro. However, both domains are needed to infe...

show abstract

Studies on tanapox virus

Cited by 53 publications

References 32 publications

Yaba-Like Disease Virus: an Alternative Replicating Poxvirus Vector for Cancer Gene Therapy

Yaba-Like Disease Virus: an Alternative Replicating Poxvirus Vector for Cancer Gene Therapy

Yaba Monkey Tumor Virus Encodes a Functional Inhibitor of Interleukin-18

A poxvirus protein forms a complex with left-handed Z-DNA: Crystal structure of a Yatapoxvirus Zα bound to DNA

Contact Info

Product

Resources

About